title: Inhibition of purified enolases from oral bacteria by fluoride.
abstract: Enolase activity in strains of oral streptococci previously has been found to be inhibited by 50% (Ki) by fluoride concentrations ranging from 50 to 300 microM or more in the presence of 0.5 to 1.0 mM inorganic phosphate ions. In this study, enolase was extracted and partly purified by a two-step process from five oral bacterial species and the effect of fluoride on the kinetics of enolase examined. The molecular weight of the putative enolase proteins was 46-48 kDa. The Vmax values ranged from 20 to 323 IU/mg and K(m) for glycerate-2-phosphate from 0.22 to 0.74 mM. Enolase activity was inhibited competitively by fluoride, with Ki values ranging from 16 to 54 microM in the presence of 5 mM inorganic phosphate ions. Ki values for phosphate ranged from 2 to 8 mM. The enolase from Streptococcus sanguis ATCC 10556 was more sensitive to fluoride (Ki = 16 +/- 2) than was enolase from Streptococcus salivarius ATCC 10575 (Ki = 19 +/- 2) or Streptococcus mutans NCTC 10449 (Ki = 40 +/- 4) and all three streptococcal strains were more sensitive to fluoride than either Actinomyces naeslundii WVU 627 (Ki = 46 +/- 6) or Lactobacillus rhamnosus ATCC 7469 (Ki = 54 +/- 6) enolases. The levels of fluoride found to inhibit the streptococcal enolases in this study are much lower than previously reported and are likely to be present in plaque, especially during acidogenesis, and could exert an anti-glycolytic effect.
authors.affiliation: Dental Research Unit, Health Research Council of New Zealand, Wellington School of Medicine, New Zealand.
authors.forename: N
authors.initials: N
authors.lastname: Guha-Chowdhury
authors.forename: A G
authors.initials: AG
authors.lastname: Clark
authors.forename: C H
authors.initials: CH
authors.lastname: Sissons
mesh_terms: D000190:Actinomyces / Q000187:drug effects / Q000201:enzymology; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002327:Cariostatic Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005459:Fluorides / Q000494:pharmacology*; D006019:Glycolysis / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D007778:Lactobacillus / Q000187:drug effects / Q000201:enzymology; D016018:Least-Squares Analysis; D009055:Mouth / Q000382:microbiology; D010710:Phosphates / Q000494:pharmacology; D010751:Phosphopyruvate Hydratase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013291:Streptococcus / Q000187:drug effects* / Q000201:enzymology*
chemical_list: D001426:Bacterial Proteins; D002327:Cariostatic Agents; D004791:Enzyme Inhibitors; D010710:Phosphates; D010751:Phosphopyruvate Hydratase; D005459:Fluorides